WuXi AppTec's STA subsidiary opens new campus in Changzhou
New site strengthens STA's position as a world-leading CDMO
WuXi AppTec, a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology and medical device industries, has announced that its small-molecule process development and manufacturing subsidiary, Shanghai SynTheAll Pharmaceutical (STA), began operations at a new, fully integrated R&D and cGMP manufacturing site in Changzhou, China, in February 2016.
The new campus is being constructed in phases. The administration building, R&D building, one large-scale manufacturing plant and supporting units are now operating, with other buildings currently under construction.
On completion, the site will employ more than 500 scientists and will add more than 1000m3 of reactor volume, doubling STA's existing R&D capacity and quadrupling its manufacturing capacity. Besides adding capacity, this state-of-the-art integrated campus will provide a unique one-site solution for STA customers to advance their active pharmaceutical ingredients (APIs) and advanced intermediates through preclinical and clinical development to global commercial launch.
‘The new site in Changzhou brings our customers added capacity, greater flexibility and the unsurpassed quality of WuXi's operations,’ said Dr Minzhang Chen, CEO of STA. ‘It further strengthens STA's position as a world-leading CDMO, offering a truly unique integrated solution to our global partners.’
‘We are pleased to open our new Changzhou site, which greatly expands our small-molecule process development and manufacturing services,’ said Dr Ge Li, Chairman and CEO of WuXi AppTec. ‘This new facility further strengthens WuXi's comprehensive, integrated open-access platform of R&D services to serve our global customers.’
